Henry Schein Q3 2026 slides: profit beats, shares fall on revenue

Henry Schein reported Q3 2026 non-GAAP EPS of $1.56, 14.7% above the $1.36 consensus, while revenue of $3.47 billion narrowly missed estimates; shares fell 5.33% premarket to $82. Adjusted EPS excluding $0.19 per share in tariff refunds grew 19.1% year over year, and the company raised full-year EPS guidance to $5.50-$5.56 from $5.29-$5.39, while keeping sales growth guidance at 4.5%-5.5%. The quarter also included $125 million of buybacks, and management said its value creation program remains on track to deliver more than $200 million in operating income improvement; investors appeared wary of the revenue miss, nonrecurring tariff benefit, and planned Q4 investment.

Analysis

The selloff is a quality-of-earnings reset, not clear evidence that operations deteriorated: the headline EPS beat is largely explained by a nonrecurring tariff benefit, while the ex-benefit result still indicates meaningful operating improvement. The more important tension is that EPS guidance rose while sales guidance did not. That raises the bar for proving margin gains are repeatable rather than dependent on mix, cost actions, or temporary benefits; planned Q4 investment also makes the next quarter a likely margin-volatility point.

Near term, price action may stay weak as investors test whether the sales outlook supports management’s double-digit 2027 EPS ambition. Over 1–3 months, watch U.S. dental internal growth, distribution margin excluding tariff effects, and Q4 investment commentary. A sustained slowdown in dental volumes or reversal of margin expansion would undermine the earnings thesis. Over 6–18 months, cloud software and company-owned products could improve mix and customer retention, but management’s AI/pricing narrative needs verification through adoption, recurring revenue, and retention metrics.

The contrarian case is that the market may be treating a small revenue miss as a broader demand signal despite reported volume-led dental share gains. However, no valuation data are provided, so the drop alone does not establish cheapness. Competitive share gains could pressure other dental distributors, including Patterson Companies, but only if they persist without margin giveback.

Key Decisions for Investors

• Do not chase the premarket decline. Consider a small, staged HSIC long only if shares stabilize and reclaim the prior close of $86.62; that offers a potential retracement of the gap, not a fundamental price target. Treat a break below the reported $82 premarket level as evidence the market is still repricing the outlook and step aside.
• For a 1–3 month thesis check, track U.S. dental merchandise internal growth and distribution operating margin excluding tariff benefits. A material deceleration in volume growth or reversal of margin expansion falsifies the operating-leverage thesis; absent those data, keep sizing conservative.
• Do not underwrite 2027 double-digit EPS growth as guidance. Verify software customer adoption/retention and whether Q4 investment produces incremental revenue; if sales guidance is cut or margin expansion stalls, reduce exposure rather than relying on buybacks to support the stock.